RxDoctor Payments Data

John Koo, MD

Psychiatry · San Francisco, CANPI 1245289594

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,396,711 of the $2,991,924 with a category attached, or 80.1%. It is spread thinly across 32 manufacturers, the largest accounting for just 19.0%. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,991,924in general payments, 2019–2025

Across 2,603 payments — averaging $1149.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$570K
  • AbbVie$425K
  • Amgen$294K
  • Sun Pharmaceutical Industries Inc.$238K
  • Pfizer$210K
  • Regeneron Healthcare Solutions, Inc.$201K
  • plus $1.1M from 26 others
$11,920in research payments, 2019–2025

Across 3 payments — averaging $3973.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$12K

What the payments were for

  • Consulting fees$190,7856%
  • Speaking & faculty fees$2,396,71180%
  • Travel & lodging$337,81611%
  • Food & beverage$62,0962%
  • Education$4,5160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,991,924 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$13,017
Medicare patients
35
Services billed
144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clobetasol Propionate24$2,426
Pimozide15$1,011

Paid to pharmacies, not to this prescriber.

Other psychiatry in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →